EU firms can scrap Iran deals if U.S. sanctions' costs too high, EU top court says

Dec 21 (Reuters) - European companies can end contracts with Iranian firms pressured by U.S. sanctions if upholding the deals would lead to "disproportionate economic loss," the EU's top court said on Tuesday.

The judgment from the European Court of Justice (ECJ) in Luxembourg was prompted by a lawsuit from the German branch of Iran's state-owned Bank Melli against Deutsche Telekom DTEGn.DE after the telecommunications provider terminated a contract with the bank in 2018 prior to its expiry.

The Higher Regional Court in Hamburg will have to decide whether upholding the contract with Bank Melli would expose Deutsche Telekom, which makes about half of its turnover with its U.S. business, to such a disproportionate economic loss.

It is not clear when the Hamburg court will make its decision.

In 2018, then U.S. president Donald Trump decided to withdraw unilaterally from the Iran nuclear deal and to re-impose sanctions on Iranian companies that had been suspended under the agreement struck in 2015.

To try to rescue the nuclear deal and its economic benefits for Iran, the European Union as a signatory issued a "blocking statute" that prohibited individuals and companies in the bloc from complying with the renewed U.S. sanctions.

The court on Tuesday backed the EU blocking statute in its ruling, saying "the prohibition imposed by EU law on complying with secondary sanctions laid down by the United States against Iran may be relied on in civil proceedings".

But the judges also said the rules of the blocking statute "cannot infringe the freedom to conduct a leading to disproportionate economic loss".

At the same time, the Hamburg judges must take into account that Deutsche Telekom did not apply for an exemption from the EU blocking statute's rules, the ECJ said.
Reporting by Sabine Siebold; editing by Barbara Lewis

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.